Phosphoproteomics guides low dose drug combination of cisplatin and silmitasertib against concurrent chemoradiation resistant cervical cancer

Cervical cancer is one of the leading causes of cancer related deaths among females. Due to proper screening programmes, most of the cervical cancer cases are presented in the locally advanced stage of the disease. Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer. However, resistance to CCRT limit the success of the treatment regimen. In this study, we investigated the altered phosphoproteome of CCRT resistant and sensitive cohort using Mass spectrometry-based proteomics. We carried out phosphoproteomic analysis of treatment naïve cervical cancer patients whose response to CCRT is recorded. The Phosphoproteomic analysis revealed kinases and the pathways associated with CCRT resistance in cervical cancer patients.